A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
Public ClinicalTrials.gov record NCT04203797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Patients With Moderate-to-Severe Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma. The secondary objectives of the study are: * To demonstrate that dupilumab treatment increases physical activity of daily living in patients with moderate-to-severe asthma * To demonstrate that dupilumab treatment improves pre- and post-exercise lung function in patients with moderate-to-severe asthma
Study identification
- NCT ID
- NCT04203797
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 15, 2020
- Primary completion
- Jul 14, 2023
- Completion
- Jul 14, 2023
- Last update posted
- Apr 17, 2024
2020 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palos Verdes Medical Group (PVMG); Peninsula Research Associates (PRA) | Rolling Hills Estates | California | 90274 | — |
| UCLA Medical Center - Harbor | Torrance | California | 90509 | — |
| Allianz Research Institute | Westminster | California | 92683 | — |
| University of Iowa Hospitals & Clinics-Roy J. and Lucille A. Carver College of Medicine | Iowa City | Iowa | 52242 | — |
| University Of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Infinity Medical Research | North Dartmouth | Massachusetts | 02747 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| American Health Research | Charlotte | North Carolina | 28277 | — |
| UH Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Temple University Hospital | Philadelphia | Pennsylvania | 19140 | — |
| Regeneron Study Site | Hendersonville | Tennessee | 37075 | — |
| The University of Texas Medical School at Houston | Houston | Texas | 77030 | — |
| Intermountain Medical Center | Murray | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04203797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 17, 2024 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04203797 live on ClinicalTrials.gov.